Bruker Corporation announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed. Biocrates is a global leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardized metabolomics accessible to laboratories worldwide.
Bruker Corporation announced that its Applied Mass Spectrometry (Applied MS) division will present a powerful lineup of innovations at the These developments reflect Bruker’s continued investment in applied markets, particularly in therapeutic drug monitoring (TDM), drugs of abuse (DoA) analysis and environmental analysis.
STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Cellular Highways Ltd from TTP Group Ltd. Cellular Highways is a biotechnology company based near Cambridge, United Kingdom, that specializes in advanced cell sorting technologies with applications in cell and gene therapy, drug discovery, and general cell research, especially where cells are fragile.
Fresenius Kabi, an operating company of Fresenius, announced that Epinephrine Injection, USP, is now available in the United States in 30 mg per 30 mL multi-dose vials.
Eden, the leading health platform connecting individuals with licensed providers and pharmacies focused on metabolic health, announced expanded access to a pharmacy-grade compounded glutathione injection protocol. The therapy is now available for eligible individuals in most states through Eden's network of licensed providers and pharmacies.
Merck known as MSD outside of the United States and Canada, announced that the Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met its primary endpoint of progression-free survival (PFS) for the treatment of patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 and in all comers.
Gensco Laboratories LLC d/b/a Gensco Pharma, a leader in specialty pharmaceuticals, proudly announces the acquisition of the global rights and intellectual property for the first and only rizatriptan Oral Dissolvable Film (ODF), which was co-developed under the trade names RizaFilm in the U.S. and both RizaFilm and RizaPort globally.
Private research nonprofit BrightFocus Foundation announced nearly $13 million in grants to support early investigative research into Alzheimer’s disease, macular degeneration, and glaucoma. This includes $7.3 million to its Alzheimer’s Disease Research program, $3.8 million to its Macular Degeneration Research program, and $1.8 million to its National Glaucoma Research program.
Kincell Bio announced the completion of a $22 million round, led by a new investor, NewSpring Capital through its dedicated healthcare strategy, NewSpring Healthcare, which invests in innovative companies in the lower-middle market that improve the delivery of healthcare or bend the cost curve through technology and human capital efficiencies.
Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, announced the commercial availability of the SOFIA™ 88 Neurovascular Support Catheter, expanding the company's stroke portfolio with a new large-bore catheter engineered for reliability, procedural flexibility, and physician control. The launch builds on the proven clinical performance and global legacy of the SOFIA™ Catheter line, which has supported more than 500,000 procedures across 170 countries over the past decade.